PMID- 34139522
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 1532-866X (Electronic)
IS  - 0049-0172 (Linking)
VI  - 51
IP  - 4
DP  - 2021 Aug
TI  - The cancer risk according to three subtypes of ANCA-associated vasculitis: A 
      propensity score-matched analysis of a nationwide study.
PG  - 692-699
LID - S0049-0172(21)00045-7 [pii]
LID - 10.1016/j.semarthrit.2021.03.014 [doi]
AB  - OBJECTIVE: It remains unknown whether cancer risk differs among the three 
      subtypes of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and 
      what the cancer risk factors are. We conducted a nationwide study in Korea to 
      evaluate the risk of cancer in patients with AAV and to identify the risk factors 
      for cancer. METHODS: We analyzed the Health Insurance Review and Assessment 
      database of Korea and identified 1982 patients diagnosed with AAV between January 
      1, 2007 and December 31, 2017. The patients and controls with no history of AAV 
      or cancer were matched 1:4 by propensity scores. The study outcome measure was 
      incidence of cancer during 11 years of follow-up. RESULTS: Patients with 
      granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and 
      eosinophilic granulomatosis with polyangiitis (EGPA) numbered 684, 606, and 692, 
      respectively. The overall incidence of cancer was higher among patients with AAV 
      than in controls (HR 1.32, 95% CI 1.08-1.61). The risk of hematological 
      malignancy, lung cancer, and bladder cancer in the GPA group, lung cancer in the 
      MPA group, and hematological malignancy in the EGPA group were significantly 
      higher than in controls (HR 7.39, 3.20, 4.20, 2.86, and 4.65, respectively). Age, 
      male sex, GPA subtype, and cyclophosphamide use were significantly associated 
      with cancer risk in patients with AAV. CONCLUSION: Overall cancer incidence was 
      increased in patients with AAV. Cancer risk was higher in patients with GPA than 
      in those with MPA or EGPA. The use of cyclophosphamide was associated with an 
      increased risk of cancer, while rituximab was not.
CI  - Copyright (c) 2021. Published by Elsevier Inc.
FAU - Choi, Sang Tae
AU  - Choi ST
AD  - Division of Rheumatology, Department of Internal Medicine, Chung-Ang University 
      College of Medicine, Seoul, South Korea.
FAU - Ahn, Song Vogue
AU  - Ahn SV
AD  - Department of Health Convergence, Ewha Womans University, Seoul, South Korea.
FAU - Lee, Poong Hoon
AU  - Lee PH
AD  - Healthcare Data Convergence Department, Health Insurance Review and Assessment 
      Service, Wonju, South Korea.
FAU - Moon, Chang Mo
AU  - Moon CM
AD  - Department of Internal Medicine, College of Medicine, Ewha Womans University, 
      Seoul, South Korea; Inflammation-Cancer Microenvironment Research Center, College 
      of Medicine, Ewha Womans University, Seoul, South Korea. Electronic address: 
      mooncm27@ewha.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210401
PL  - United States
TA  - Semin Arthritis Rheum
JT  - Seminars in arthritis and rheumatism
JID - 1306053
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/epidemiology
MH  - *Churg-Strauss Syndrome
MH  - *Granulomatosis with Polyangiitis/epidemiology
MH  - Humans
MH  - Male
MH  - *Microscopic Polyangiitis
MH  - *Neoplasms/epidemiology
MH  - Propensity Score
OTO - NOTNLM
OT  - Antineutrophilic cytoplasmic antibody
OT  - Cancer
OT  - Cyclophosphamide
OT  - Rituximab
OT  - Vasculitis
EDAT- 2021/06/18 06:00
MHDA- 2023/02/25 06:00
CRDT- 2021/06/17 20:19
PHST- 2020/11/28 00:00 [received]
PHST- 2021/03/26 00:00 [revised]
PHST- 2021/03/30 00:00 [accepted]
PHST- 2021/06/18 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2021/06/17 20:19 [entrez]
AID - S0049-0172(21)00045-7 [pii]
AID - 10.1016/j.semarthrit.2021.03.014 [doi]
PST - ppublish
SO  - Semin Arthritis Rheum. 2021 Aug;51(4):692-699. doi: 
      10.1016/j.semarthrit.2021.03.014. Epub 2021 Apr 1.